<DOC>
	<DOCNO>NCT02149030</DOCNO>
	<brief_summary>The main objective study identify whether inform infrequently result screen : 1 ) At least safe accurate frequently obtain information present combination opportunistic/organized cervical screening compare regimen result three screen visit age 22 , 25 30 year ( Arm A1 ) vs. result one screen visit age 30 year ( Arm A2 ) Human papillomavirus ( HPV ) vaccinate young woman .</brief_summary>
	<brief_title>Effectiveness Cervical Screening HPV Vaccinated Women</brief_title>
	<detailed_description>Altogether 16.500 1992-1995 born woman vaccinate bi-valent human papillomavirus type 16 18 ( HPV16/18 ) vaccine adolescent either age 12 15 age 18 invited effectiveness trial age 22 year , randomize Arms A1 A2 , A3 , respectively . Cervical sample cervico-vaginal self-samples rinse first-void urine analyse HPV C. trachomatis DNA MGP primer system follow MALDITOF mass spectrometry SEQUENOM platform ( HPV ) Abbottâ„¢ PCR ( Chlamydia trachomatis ) , respectively . With assumed &gt; 50 % participation trial 80 % power show non-inferiority infrequent vs. frequent screen information . A one-way ( participant ) blind interim analysis among 1992-born study participant A1 A3 arm , attend 2nd study visit age 25 year , perform 2017 assure statistically significant difference cervical intraepithelial neoplasia grade 2/3 ( CIN2/CIN3 ) incidences two arm . At study end test null hypothesis difference incidence CIN2/3 end-points A1 A2 intervention arm do use Mantel-Haenszel one degree freedom chi-square statistic .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<criteria>HPV 16/18 vaccinate . Born 19921995 . Immunocompromising disease . HPV 6/11/16/18 vaccination .</criteria>
	<gender>Female</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>